Nucleic Acid Therapeutics CDMO Market Size, Growth, & Share-2031

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Nucleic Acid Therapeutics CDMO Market Size Analysis

Global Nucleic Acid Therapeutics CDMO Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Standard Nucleic Acid
  1. By Value
3. Micro-Scale Nucleic Acid
  1. By Value
4. Large-Scale Nucleic Acid
  1. By Value
5. Custom Nucleic Acid
  1. By Value
6. Modified Nucleic Acid
  1. By Value
7. Primers
  1. By Value
8. Probes
  1. By Value
9. Other Nucleic Acid
  1. By Value
10. Other Services
  1. By Value
By Chemical Synthesis
1. Introduction
  1. Chemical Synthesis By Value
2. Solid-Phase Oligonucleotide Synthesis
  1. By Value
3. Liquid-Phase Oligonucleotide Synthesis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Column-Based Method
  1. By Value
3. Microarray-Based Method
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
3. Academic Research Institute
  1. By Value
4. Diagnostic Laboratories
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Standard Nucleic Acid
  1. By Value
3. Micro-Scale Nucleic Acid
  1. By Value
4. Large-Scale Nucleic Acid
  1. By Value
5. Custom Nucleic Acid
  1. By Value
6. Modified Nucleic Acid
  1. By Value
7. Primers
  1. By Value
8. Probes
  1. By Value
9. Other Nucleic Acid
  1. By Value
10. Other Services
  1. By Value
By Chemical Synthesis
1. Introduction
  1. Chemical Synthesis By Value
2. Solid-Phase Oligonucleotide Synthesis
  1. By Value
3. Liquid-Phase Oligonucleotide Synthesis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Column-Based Method
  1. By Value
3. Microarray-Based Method
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
3. Academic Research Institute
  1. By Value
4. Diagnostic Laboratories
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Standard Nucleic Acid
    1. By Value
  3. Micro-Scale Nucleic Acid
    1. By Value
  4. Large-Scale Nucleic Acid
    1. By Value
  5. Custom Nucleic Acid
    1. By Value
  6. Modified Nucleic Acid
    1. By Value
  7. Primers
    1. By Value
  8. Probes
    1. By Value
  9. Other Nucleic Acid
    1. By Value
  10. Other Services
    1. By Value
2. By Chemical Synthesis
  1. Introduction
    1. Chemical Synthesis By Value
  2. Solid-Phase Oligonucleotide Synthesis
    1. By Value
  3. Liquid-Phase Oligonucleotide Synthesis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Column-Based Method
    1. By Value
  3. Microarray-Based Method
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Academic Research Institute
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Standard Nucleic Acid
  1. By Value
3. Micro-Scale Nucleic Acid
  1. By Value
4. Large-Scale Nucleic Acid
  1. By Value
5. Custom Nucleic Acid
  1. By Value
6. Modified Nucleic Acid
  1. By Value
7. Primers
  1. By Value
8. Probes
  1. By Value
9. Other Nucleic Acid
  1. By Value
10. Other Services
  1. By Value
By Chemical Synthesis
1. Introduction
  1. Chemical Synthesis By Value
2. Solid-Phase Oligonucleotide Synthesis
  1. By Value
3. Liquid-Phase Oligonucleotide Synthesis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Column-Based Method
  1. By Value
3. Microarray-Based Method
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
3. Academic Research Institute
  1. By Value
4. Diagnostic Laboratories
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Standard Nucleic Acid
    1. By Value
  3. Micro-Scale Nucleic Acid
    1. By Value
  4. Large-Scale Nucleic Acid
    1. By Value
  5. Custom Nucleic Acid
    1. By Value
  6. Modified Nucleic Acid
    1. By Value
  7. Primers
    1. By Value
  8. Probes
    1. By Value
  9. Other Nucleic Acid
    1. By Value
  10. Other Services
    1. By Value
2. By Chemical Synthesis
  1. Introduction
    1. Chemical Synthesis By Value
  2. Solid-Phase Oligonucleotide Synthesis
    1. By Value
  3. Liquid-Phase Oligonucleotide Synthesis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Column-Based Method
    1. By Value
  3. Microarray-Based Method
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Academic Research Institute
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Standard Nucleic Acid
  1. By Value
3. Micro-Scale Nucleic Acid
  1. By Value
4. Large-Scale Nucleic Acid
  1. By Value
5. Custom Nucleic Acid
  1. By Value
6. Modified Nucleic Acid
  1. By Value
7. Primers
  1. By Value
8. Probes
  1. By Value
9. Other Nucleic Acid
  1. By Value
10. Other Services
  1. By Value
By Chemical Synthesis
1. Introduction
  1. Chemical Synthesis By Value
2. Solid-Phase Oligonucleotide Synthesis
  1. By Value
3. Liquid-Phase Oligonucleotide Synthesis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Column-Based Method
  1. By Value
3. Microarray-Based Method
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
3. Academic Research Institute
  1. By Value
4. Diagnostic Laboratories
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Standard Nucleic Acid
    1. By Value
  3. Micro-Scale Nucleic Acid
    1. By Value
  4. Large-Scale Nucleic Acid
    1. By Value
  5. Custom Nucleic Acid
    1. By Value
  6. Modified Nucleic Acid
    1. By Value
  7. Primers
    1. By Value
  8. Probes
    1. By Value
  9. Other Nucleic Acid
    1. By Value
  10. Other Services
    1. By Value
2. By Chemical Synthesis
  1. Introduction
    1. Chemical Synthesis By Value
  2. Solid-Phase Oligonucleotide Synthesis
    1. By Value
  3. Liquid-Phase Oligonucleotide Synthesis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Column-Based Method
    1. By Value
  3. Microarray-Based Method
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Academic Research Institute
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Standard Nucleic Acid
  1. By Value
3. Micro-Scale Nucleic Acid
  1. By Value
4. Large-Scale Nucleic Acid
  1. By Value
5. Custom Nucleic Acid
  1. By Value
6. Modified Nucleic Acid
  1. By Value
7. Primers
  1. By Value
8. Probes
  1. By Value
9. Other Nucleic Acid
  1. By Value
10. Other Services
  1. By Value
By Chemical Synthesis
1. Introduction
  1. Chemical Synthesis By Value
2. Solid-Phase Oligonucleotide Synthesis
  1. By Value
3. Liquid-Phase Oligonucleotide Synthesis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Column-Based Method
  1. By Value
3. Microarray-Based Method
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
3. Academic Research Institute
  1. By Value
4. Diagnostic Laboratories
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Standard Nucleic Acid
    1. By Value
  3. Micro-Scale Nucleic Acid
    1. By Value
  4. Large-Scale Nucleic Acid
    1. By Value
  5. Custom Nucleic Acid
    1. By Value
  6. Modified Nucleic Acid
    1. By Value
  7. Primers
    1. By Value
  8. Probes
    1. By Value
  9. Other Nucleic Acid
    1. By Value
  10. Other Services
    1. By Value
2. By Chemical Synthesis
  1. Introduction
    1. Chemical Synthesis By Value
  2. Solid-Phase Oligonucleotide Synthesis
    1. By Value
  3. Liquid-Phase Oligonucleotide Synthesis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Column-Based Method
    1. By Value
  3. Microarray-Based Method
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Academic Research Institute
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Standard Nucleic Acid
  1. By Value
3. Micro-Scale Nucleic Acid
  1. By Value
4. Large-Scale Nucleic Acid
  1. By Value
5. Custom Nucleic Acid
  1. By Value
6. Modified Nucleic Acid
  1. By Value
7. Primers
  1. By Value
8. Probes
  1. By Value
9. Other Nucleic Acid
  1. By Value
10. Other Services
  1. By Value
By Chemical Synthesis
1. Introduction
  1. Chemical Synthesis By Value
2. Solid-Phase Oligonucleotide Synthesis
  1. By Value
3. Liquid-Phase Oligonucleotide Synthesis
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Column-Based Method
  1. By Value
3. Microarray-Based Method
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical Companies
  1. By Value
3. Academic Research Institute
  1. By Value
4. Diagnostic Laboratories
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Standard Nucleic Acid
    1. By Value
  3. Micro-Scale Nucleic Acid
    1. By Value
  4. Large-Scale Nucleic Acid
    1. By Value
  5. Custom Nucleic Acid
    1. By Value
  6. Modified Nucleic Acid
    1. By Value
  7. Primers
    1. By Value
  8. Probes
    1. By Value
  9. Other Nucleic Acid
    1. By Value
  10. Other Services
    1. By Value
2. By Chemical Synthesis
  1. Introduction
    1. Chemical Synthesis By Value
  2. Solid-Phase Oligonucleotide Synthesis
    1. By Value
  3. Liquid-Phase Oligonucleotide Synthesis
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Column-Based Method
    1. By Value
  3. Microarray-Based Method
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical Companies
    1. By Value
  3. Academic Research Institute
    1. By Value
  4. Diagnostic Laboratories
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Nucleic Acid Therapeutics CDMO Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Bachem Holding AG
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Biospring GmbH
Danaher Corporation
Guangzhou Ruibo Biotechnology Co.Ltd.
LGC Limited
Merck KGaA
Nippon Shokubai Co.Ltd.
QIAGEN N.V.
ST Pharm Co Ltd
Nitto Denko Avecia Inc.
Sumitomo Chemical Co.Ltd.
Thermo Fisher Scientific Inc.
Wuxi AppTec
Syngene International Limited

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment